Latest news with #Mrs.CherylannPinto
Economic Times
29-05-2025
- Business
- Economic Times
I-Sec maintains Reduce call on Glenmark Pharma, raises target price to Rs 1,300
ICICI Securities has maintained a Reduce call on Glenmark Pharmaceuticals with a revised target price of Rs 1,300 (earlier Rs 1,265). The current market price of Glenmark is Rs 1383.9. Glenmark Pharmaceuticals, incorporated in 1977, is a Mid Cap company with a market cap of Rs 39083.06 crore. Glenmark Pharma's key products/revenue segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the year ending 31-Mar-2023. ADVERTISEMENT Financials For the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 3267.89 crore, down -4.41 % from last quarter Total Income of Rs 3418.68 crore and down -14.81% from last year same quarter Total Income of Rs 3836.12 crore. The company has reported net profit after tax of Rs 4.38 crore in the latest quarter. The company's top management includes Saldanha, Pinto, Mr.V S Mani, Mrs.B E Saldanha, Ramasastry, Iyer, V Desai, Bhattacharjee. Company has Walker, Chandiok & as its auditors. As on 31-03-2025, the company has a total of 28 crore shares outstanding. Investment RationaleThe stock currently trades at valuations of 23.8x FY26E and 19.3x FY27E earnings, and EV/EBITDA multiples of 14.5x FY26E and 11.9x FY27E, respectively. ICICI Securities cuts revenue and EBITDA by ~2% each for FY26/27E to factor in slower growth in India. Enhanced free cash generation and maintaining a prudent balance sheet are essential avenues to be watched out in quarters ahead. Thy expect 10.3%/15.0%/20.8% revenue/ EBITDA/PAT CAGR over FY25-27E, with EBITDA margin at 19.4% in FY27E. I-Sec maintains a REDUCE call with higher target price of Rs 1,300 (earlier Rs 1,265), based on 18x FY27E EPS (22x FY26E EPS previously). Key upside risks: Healthy launches, faster recovery in the US. Promoter/FII Holdings Promoters held 46.65 per cent stake in the company as of 31-Mar-2025, while FIIs owned 23.15 per cent, DIIs 14.6 per cent. (You can now subscribe to our ETMarkets WhatsApp channel) Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.
Time of India
29-05-2025
- Business
- Time of India
I-Sec maintains Reduce call on Glenmark Pharma, raises target price to Rs 1,300
ICICI Securities has maintained a Reduce call on Glenmark Pharmaceuticals with a revised target price of Rs 1,300 (earlier Rs 1,265). The current market price of Glenmark is Rs 1383.9. Glenmark Pharmaceuticals, incorporated in 1977, is a Mid Cap company with a market cap of Rs 39083.06 crore. Glenmark Pharma 's key products/revenue segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the year ending 31-Mar-2023. Financials by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Affordable Apartments for Rent in Basabo Apartments for rent | Search Ads Learn More Undo For the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 3267.89 crore, down -4.41 % from last quarter Total Income of Rs 3418.68 crore and down -14.81% from last year same quarter Total Income of Rs 3836.12 crore. The company has reported net profit after tax of Rs 4.38 crore in the latest quarter. The company's top management includes Saldanha, Pinto, Mr.V S Mani, Mrs.B E Saldanha, Ramasastry, Iyer, V Desai, Bhattacharjee. Company has Walker, Chandiok & as its auditors. As on 31-03-2025, the company has a total of 28 crore shares outstanding. Investment Rationale The stock currently trades at valuations of 23.8x FY26E and 19.3x FY27E earnings, and EV/EBITDA multiples of 14.5x FY26E and 11.9x FY27E, respectively. ICICI Securities cuts revenue and EBITDA by ~2% each for FY26/27E to factor in slower growth in India. Enhanced free cash generation and maintaining a prudent balance sheet are essential avenues to be watched out in quarters ahead. Thy expect 10.3%/15.0%/20.8% revenue/ EBITDA/PAT CAGR over FY25-27E, with EBITDA margin at 19.4% in FY27E. I-Sec maintains a REDUCE call with higher target price of Rs 1,300 (earlier Rs 1,265), based on 18x FY27E EPS (22x FY26E EPS previously). Key upside risks: Healthy launches, faster recovery in the US. Live Events Promoter/FII Holdings Promoters held 46.65 per cent stake in the company as of 31-Mar-2025, while FIIs owned 23.15 per cent, DIIs 14.6 per cent.
